Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.67 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.67 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.67 |
| ▸ | DRD3 | P35462 | 6/20 | 0.67 |
| ▸ | DRD4 | P21917 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | DRD1 | P21728 | 3/20 | 0.67 |
| ▸ | HTR2C | P28335 | 3/20 | 0.67 |
| ▸ | HTR2B | P41595 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 3/20 | 0.67 |
| ▸ | HTR6 | P50406 | 3/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.67 |
| ▸ | HTR3B | O95264 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842045 | 0.84 | DRD2 (0.87) | DRD2DRD3HTR1AHTR2ADRD4 | |
| SCHEMBL1837864 | 0.82 | DRD2 (0.82) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL4774002 | 0.82 | HTR2A (1.00) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL28028 | 0.82 | HTR2A (1.00) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL29368426 | 0.82 | HTR2A (1.00) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL4914143 | 0.81 | HTR2A (0.98) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL374870 | 0.81 | HTR2A (0.98) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL3143295 | 0.81 | HTR2A (0.98) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL5859456 | 0.81 | HTR2A (0.98) | DRD2DRD3HTR1AHTR2ADRD4 | |
| Ziprasidone SCHEMBL3139060 | 0.81 | HTR2A (0.98) | DRD2DRD3HTR1AHTR2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-07-16 | — | — | US | disclosed |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10112903-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-10-30 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| EP-2445502-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-03 | — | — | US | disclosed |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | MORGAN STANLEY SENIOR FUNDING, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LTD (IE) | 2014-11-27 | — | — | US | disclosed |
| US-8796276-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8431576-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-04-30 | — | — | US | disclosed |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LIMITED | 2013-04-18 | — | — | US | disclosed |
| EP-2445502-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| WO-2010151689-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-10112903-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DRD2 183/4885HTR1A 171/4885HTR2A 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.